Novavax Stock News

Novavax Inc. unveiled on Thursday that it has started on the initial steps required to manufacture an Omicron-specific coronavirus vaccine, with the manufacturing of the vaccine in a commercial facili

(PR-inside.com) SAN FRANCISCO, CA / ACCESSWIRE / December 2, 2021 / Hagens Berman urges Novavax, Inc. (NASDAQ:NVAX) investors with significant losses to submit your losses now. Class Period: Mar. 2, 2021 - Oct. 19, 2021 Lead Plaintiff Deadline: Jan. 11, 2022 Visit: www.hbsslaw.com/investor-fraud/NVAX Contact An Attorney Now: [email protected] 844-916-0895 Novavax, Inc. (NVAX) Securities Fraud Class Action: The lawsuit alleges that Defendants misrepresented Novavax''s progress toward successfully developing its COVID-19 vaccine (NVX-CoV2373), including: (1) overstating Novavax''s manufacturing capabilities and downplaying manufacturing issues that would impact the approval timeline for NVX-CoV2373; (2) concealing that Novavax was unlikely to meet its anticipated EUA regulatory timelines; (3) exaggerating the regulatory and commercial ..

In short: Not really.

NEW YORK, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn''t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor''s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

SAN DIEGO--(BUSINESS WIRE)---- $NVAX #COVID19--Novavax, Inc. (NVAX) Misled Shareholders Regarding Approval of its COVID Vaccine

The world''s biggest vaccine maker exported 137,500 doses of Covovax, as it calls the shot, to the Southeast Asian country last week

Serum Institute of India (SII) has exported its first Novavax doses to Indonesia by the COVAX network, the Indian government declared. The worlds biggest vaccine maker exported 1,37,500 doses of Covovax to Indonesia last week. Indonesia has already approved the Novavax dose, but India and the World Health Organization (WHO) The post SII Exports 1st Novavax Dose Through COVAX appeared first on Equitypandit .

Exported 137,500 doses of Covovax to Indonesia

CEDARHURST, N.Y., Nov. 30, 2021 (GLOBE NEWSWIRE) -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Höegh LNG Partners LP (HMLP) Class Period: August 22, 2019 and July 27, 2021 Lead Plaintiff Motion Deadline: December 27, 2021 SECURITIES FRAUD To learn more, visit https://kclasslaw.com/cases/securities/nyse-hmlp/ ON24, Inc. (ONTF) Class Period: purchase of shares issued either in or after the February 2021 Initial Public Offering Lead Plaintiff Motion Deadline: January 3, 2022 MISLEADING PROSPECTUS To learn more, visit https://kclasslaw.com/cases/securities/nyse-ontf/ Novavax, Inc. (NVAX) Class Period: March Full story available on Benzinga.com

Read more about India''s Serum Institute delivers first Novavax shot through COVAX on Devdiscourse

The Novavax two-dose shot is made with lab-grown copies of the spike protein that coats the coronavirus.

BRUSSELS: Vaccines specially adapted for the new Omicron coronavirus variant could be approved in three to four months if they are needed, the head of the EUs drug regulator said on Tuesday. The decision on whether new shots are required would, however, have to be made by other bodies, European Medicines Agency Executive Director Emer Cooke said. Were there a need to change the existing vaccines, we could be in a position to have those approved within three to four months, Cooke told a European Parliament committee. Thats from the start of the time when they would start to change. Her comments come after the head of US vaccine maker Moderna was quoted as saying that existing jabs will struggle against the heavily mutated Omicron. Moderna has already said it is working on an Omicron-specific vaccine, as is US rival Pfizer. Cooke said EU regulators dont know yet whether the current vaccines remain effective against Omicron which she said would take about two weeks to find out or whether new ones are needed. A decision needs to be made first whether thats necessary, and thats not a decision for the European Medicines Agency, Cooke said.

(PR-inside.com) NEW YORK, NY / ACCESSWIRE / November 30, 2021 / Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion no later than January 18, 2022 in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Novavax, Inc. ("Novavax") (NASDAQ:NVAX) between March 2, 2021 and October 19, 2021, inclusive (the "Class Period"). The lawsuit was filed in the United States District Court for the District of Maryland and alleges violations of the Securities Exchange Act of 1934. If you purchased ..

Novavax, Inc. (NASDAQ:NVAX) shares traded up 3.9% on Tuesday . The company traded as high as $205.29 and last traded at $201.50. 69,274 shares changed hands during trading, a decline of 99% from the average session volume of 4,631,432 shares. The stock had previously closed at $193.96. A number of equities research analysts recently weighed []